Elisabeth Tweesteden Ziekenhuis /ID# 163631

Tilburg 5022 GC

0 studies enrolling now · 1 studies all time

What they study most

Crohn's Disease

Studies at this site

• A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease — Completed